| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
68,788,000 |
| Market
Cap: |
2.16(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$14.19 - $52.31 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Arvinas is a biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies to degrade disease-causing proteins. Co. is developing ARV-110, a proteolysis targeting chimeras (PROTAC) targeted protein degrader targeting the androgen receptor protein for the treatment of men with metastatic castration-resistant prostate cancer. Co. is also developing ARV-471, a PROTAC targeted protein degrader targeting the estrogen receptor protein, or ER, for the treatment of patients with locally advanced or metastatic ER positive / HER2 negative breast cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
10,298 |
10,298 |
11,622 |
21,554 |
| Total Sell Value |
$484,521 |
$484,521 |
$516,810 |
$859,747 |
| Total People Sold |
4 |
4 |
4 |
4 |
| Total Sell Transactions |
4 |
4 |
5 |
9 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Houston John G |
President and CEO |
• • – |
2020-03-23 |
4 |
OE |
$16.00 |
$100,000 |
D/D |
6,250 |
816,200 |
|
- |
|
| Cassidy Sean A |
Chief Financial Officer |
• – – |
2020-03-23 |
4 |
OE |
$16.00 |
$128,480 |
D/D |
8,030 |
160,422 |
|
- |
|
| Shannon Timothy M |
Director |
– • – |
2020-03-20 |
4 |
B |
$40.00 |
$100,000 |
D/D |
2,500 |
61,623 |
2.39 |
-21% |
|
| Cassidy Sean A |
Chief Financial Officer |
• – – |
2020-03-19 |
4 |
S |
$37.61 |
$56,942 |
D/D |
(1,514) |
152,392 |
|
20% |
|
| Cassidy Sean A |
Chief Financial Officer |
• – – |
2020-03-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,791 |
153,906 |
|
- |
|
| Houston John G |
President and CEO |
• • – |
2020-03-19 |
4 |
S |
$37.61 |
$203,282 |
D/D |
(5,405) |
809,950 |
|
20% |
|
| Houston John G |
President and CEO |
• • – |
2020-03-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,511 |
815,355 |
|
- |
|
| Taylor Ian |
Chief Scientific Officer |
• – – |
2020-03-19 |
4 |
S |
$37.61 |
$31,066 |
D/D |
(826) |
70,398 |
|
20% |
|
| Taylor Ian |
Chief Scientific Officer |
• – – |
2020-03-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,686 |
71,224 |
|
- |
|
| Margus Bradley Albert |
Director |
– • – |
2020-03-18 |
4 |
S |
$37.46 |
$1,498,400 |
D/D |
(40,000) |
59,463 |
|
12% |
|
| Cassidy Sean A |
Chief Financial Officer |
• – – |
2020-02-07 |
4 |
AS |
$49.97 |
$510,157 |
D/D |
(10,000) |
149,115 |
|
-41% |
|
| Taylor Ian |
Chief Scientific Officer |
• – – |
2020-01-28 |
4 |
OE |
$16.00 |
$208,672 |
D/D |
13,042 |
68,538 |
|
- |
|
| Houston John G |
President and CEO |
• • – |
2019-12-17 |
4 |
OE |
$16.00 |
$200,000 |
D/D |
12,500 |
797,844 |
|
- |
|
| Ratcliffe Liam |
Director |
– • – |
2019-11-12 |
4 |
B |
$22.00 |
$14,960,000 |
I/I |
680,000 |
680,000 |
2.1 |
- |
|
| Taylor Ian |
Chief Scientific Officer |
• – – |
2019-11-05 |
4 |
AS |
$23.55 |
$236,000 |
D/D |
(10,000) |
65,496 |
|
- |
|
| Taylor Ian |
Chief Scientific Officer |
• – – |
2019-09-30 |
4 |
AS |
$21.76 |
$218,614 |
D/D |
(10,000) |
75,496 |
|
- |
|
| Parmar Kush |
Director |
– • – |
2019-09-24 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,700 |
1,775 |
|
- |
|
| Parmar Kush |
Director |
– • – |
2019-09-16 |
4 |
A |
$0.00 |
$0 |
D/D |
3,475 |
3,475 |
|
- |
|
| Schwab Andrew J. |
10% Owner |
– – • |
2019-09-16 |
4 |
A |
$0.00 |
$0 |
I/I |
137,636 |
1,002 |
|
- |
|
| Schwab Andrew J. |
10% Owner |
– – • |
2019-09-16 |
4 |
D |
$0.00 |
$0 |
I/I |
(450,000) |
79,856 |
|
- |
|
| Cassidy Sean A |
Chief Financial Officer |
• – – |
2019-08-07 |
4 |
OE |
$16.00 |
$100,000 |
D/D |
6,250 |
169,115 |
|
- |
|
| Cassidy Sean A |
Chief Financial Officer |
• – – |
2019-07-29 |
4 |
AS |
$26.13 |
$313,245 |
D/D |
(11,945) |
162,865 |
|
- |
|
| Schwab Andrew J. |
10% Owner |
– – • |
2019-06-28 |
4 |
S |
$22.02 |
$7,927,200 |
I/I |
(360,000) |
91,162 |
|
- |
|
| Schwab Andrew J. |
10% Owner |
– – • |
2019-06-27 |
4 |
S |
$21.75 |
$9,787,500 |
I/I |
(450,000) |
100,207 |
|
- |
|
| Canaan Partners Ix Llc |
10% Owner |
– – • |
2019-06-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(500,000) |
4,489,554 |
|
- |
|
174 Records found
|
|
Page 6 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.21 (0.67%) 
